Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Middle East Pharmaceutical Industries Co Debt-to-EBITDA?
Middle East Pharmaceutical Industries CoSAU:4016 -0.67%21 Debt-to-EBITDA is 0.70 as of Jun. 2026, which is 19% above its 10-year median of 0.59. GuruFocus rates SAU:4016 with a GF Score™ of 21/100. The stock has 3 warning signs investors should review. Among 679 Drug Manufacturers companies, Middle East Pharmaceutical Industries Co ranks better than 65.83% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Middle East Pharmaceutical Industries Co Debt-to-EBITDA Related Terms
Middle East Pharmaceutical Industries Co Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Middle East Pharmaceutical Industries Co Debt-to-EBITDA Chart
Middle East Pharmaceutical Industries Co Annual Data
Trend
Dec23
Dec24
Dec25
Debt-to-EBITDA
0.69
0.59
0.50
Middle East Pharmaceutical Industries Co Quarterly Data
SAU:4016 vs ZTS, UTHR, VTRS: Debt-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Middle East Pharmaceutical Industries Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Middle East Pharmaceutical Industries Co Debt-to-EBITDA vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Middle East Pharmaceutical Industries Co (SAU:4016) has a Debt-to-EBITDA of 0.70 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Middle East Pharmaceutical Industries Co. This is 19% above median its historical median of 0.59. Over the past decade, Middle East Pharmaceutical Industries Co's Debt-to-EBITDA has ranged from 0.50 to 0.78. According to the industry distribution chart, Middle East Pharmaceutical Industries Co ranks #232 out of 679 companies in the Drug Manufacturers industry, placing it in the top 34.2%.
Is Middle East Pharmaceutical Industries Co's Debt-to-EBITDA too high?
Middle East Pharmaceutical Industries Co's current Debt-to-EBITDA of 0.70 is 19% above median its 10-year median of 0.59. Over the past 10 years, this metric has ranged from a low of 0.50 to a high of 0.78. The Drug Manufacturers industry median Debt-to-EBITDA is 1.64. Middle East Pharmaceutical Industries Co's value of 0.70 is 57.3% below this industry median. Based on the distribution chart, Middle East Pharmaceutical Industries Co ranks #232 out of 679 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Middle East Pharmaceutical Industries Co has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Middle East Pharmaceutical Industries Co's Debt-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Middle East Pharmaceutical Industries Co ranks #232 out of 679 companies for Debt-to-EBITDA. This puts Middle East Pharmaceutical Industries Co in the upper half of its industry. The industry median Debt-to-EBITDA is 1.64. Middle East Pharmaceutical Industries Co's value of 0.70 is 57.3% below this benchmark. Historically, Middle East Pharmaceutical Industries Co's own Debt-to-EBITDA has ranged from 0.50 to 0.78 over the past decade. While the company's 10-year median is 0.59 vs. the industry median of 1.64, Middle East Pharmaceutical Industries Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.64, based on 679 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Middle East Pharmaceutical Industries Co's current Debt-to-EBITDA of 0.70 is 57.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Middle East Pharmaceutical Industries Co. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Middle East Pharmaceutical Industries Co's current Debt-to-EBITDA is 0.70, which is 19% above median its own 10-year median of 0.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Middle East Pharmaceutical Industries Co stock overvalued right now?
Middle East Pharmaceutical Industries Co (SAU:4016) has a current Debt-to-EBITDA of 0.70. The current Debt-to-EBITDA is 0.70, which is 19% above median its 10-year median of 0.59 and 57.3% below the Drug Manufacturers industry median of 1.64. Middle East Pharmaceutical Industries Co's overall GF Score™ is 21/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Middle East Pharmaceutical Industries Co (SAU:4016), the current Debt-to-EBITDA is 0.70 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Middle East Pharmaceutical Industries Co is a holding company engaged in manufacturing medicines, medicated and non-medicated creams and gels. The company operates in Private, Public, and Export segments. Geographically, it generates the majority of its revenue from Saudi Arabia.
21GF Score
Get the complete analysis for SAU:4016
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SAU:4016 has been successfully added to your 
